Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo

Geng, Shan; Qin, Limei; He, Yirui; Li, Xinrun; Yang, Gangyi; Liu, Dongfang; Li, Yongsheng

doi:10.1016/j.biomaterials.2021.120763

Cited by 20 publications

(12 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study also supported that sustained release of a GLP-1 and FGF21 dual agonist can protect diabetic mice from hyperglycemia 136 . In addition, a drug delivery system used for the delivery of GLP-1 and FGF21 in vitro and in vivo was developed 137 . Mesenchymal stem cells modified by FGF21 and GLP-1 transplantation are another way to combine GLP-1 and FGF21.…”

Section: Fgf21 and Metabolic Diseasesmentioning

confidence: 99%

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Tan¹,

Tong²,

Chen³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Cardiovascular and metabolic disease (CVMD) is becoming increasingly prevalent in developed and developing countries with high morbidity and mortality. In recent years, fibroblast growth factor 21 (FGF21) has attracted intensive research interest due to its purported role as a potential biomarker and critical player in CVMDs, including atherosclerosis, coronary artery disease, myocardial infarction, hypoxia/reoxygenation injury, heart failure, type 2 diabetes, obesity, and nonalcoholic steatohepatitis. This review summarizes the recent developments in investigating the role of FGF21 in CVMDs and explores the mechanism whereby FGF21 regulates the development of CVMDs. Novel molecular targets and related pathways of FGF21 (adenosine 5'-monophosphate-activated protein kinase, silent information regulator 1, autophagy-related molecules, and gut microbiota-related molecules) are highlighted in this review. Considering the poor pharmacokinetics and biophysical properties of native FGF21, the development of new generations of FGF21-based drugs has tremendous therapeutic potential. Related preclinical and clinical studies are also summarized in this review to foster clinical translation. Thus, our review provides a timely and insightful overview of the physiology, biomarker potential, molecular targets, and therapeutic potential of FGF21 in CVMDs.

show abstract

Section: Fgf21 and Metabolic Diseasesmentioning

confidence: 99%

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Tan¹,

Tong²,

Chen³

et al. 2023

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…[95] Liraglutide and FGF-21 plasmid were delivered to Hepa1-6 cells and HFD-fed male C57BL/6J mice and by using amino-functionalised dual-mesoporous silica nanoparticles (N-EDMSN) to examine their synergistic effect. [96] N-EDMSN successfully convey FGF-21 plasmids and liraglutide and delivered them in Hepa1-6 cells. A greater in vitro transfection efficacy of N-EDMSNs was observed compared to Lipofectamine 2000.…”

Section: Delivery Of Glp-1 and Its Agonistsmentioning

confidence: 99%

“…In HFD-fed animals, NEDMSN administration dramatically decreased food intake, body weight, and blood glucose and enhanced energy dissipation, and restored hepatic insulin sensitivity. [96]…”

Section: Delivery Of Glp-1 and Its Agonistsmentioning

confidence: 99%

Mesoporous Silica Nanoparticles: Drug Delivery Vehicles for Antidiabetic Molecules

et al. 2023

View full text Add to dashboard Cite

Mesoporous silica nanoparticles (MSNs) are promising nanomaterials that are widely used in biomedical applications like drug delivery, diagnosis, bio-sensing and cell tracking. MSNs have been investigated meticulously in the drug-delivery field due to their unique chemical and pharmacokinetic properties, such as highly ordered mesopores, high surface area and pore volume, tuneable pore size, stability, surface functionalisation, and biocompatibility. MSN-based nanocomposites have been used to deliver therapeutic molecules like insulin, GLP-1, exenatide, DPP-4 inhibitor and plasmid-containing GLP-1 genes for managing diabetes mellitus for the last decade. The functionalisation properties of MSNs make them substantially capable of the co-delivery, controlled delivery and stimuliresponsive delivery of antidiabetic drugs. This review focuses on the delivery of antidiabetic therapeutics with special emphasis on the functionalisation of MSNs and stimuliresponsive delivery.

show abstract

“…Another interesting example, reported by Niu, Yang and coworkers, focused on the treatment of diabetes. These authors created a nanosystem able to transfect two plasmids: the fibroblast growth factor 21 (FGF-21, known to improve glucose metabolism and insulin resistance) and Liraglutide, an analog of the Glucagon-like peptide-1 (GLP-1) with a hypoglycemic effect [ 63 ]. The nanosystem, based on hierarchically porous silica nanospheres [ 85 ], was able to load and deliver both therapeutics, and in particular the FGF-21-containing plasmid with higher efficacy than Lipofectamine 2000.…”

Section: Development Of Silica-based Nanomedicines Using Therapeutic ...mentioning

confidence: 99%

Delivery of Therapeutic Biopolymers Employing Silica-Based Nanosystems

2023

View full text Add to dashboard Cite

The use of nanoparticles is crucial for the development of a new generation of nanodevices for clinical applications. Silica-based nanoparticles can be tailored with a wide range of functional biopolymers with unique physicochemical properties thus providing several advantages: (1) limitation of interparticle interaction, (2) preservation of cargo and particle integrity, (3) reduction of immune response, (4) additional therapeutic effects and (5) cell targeting. Therefore, the engineering of advanced functional coatings is of utmost importance to enhance the biocompatibility of existing biomaterials. Herein we will focus on the most recent advances reported on the delivery and therapeutic use of silica-based nanoparticles containing biopolymers (proteins, nucleotides, and polysaccharides) with proven biological effects.

show abstract

Effective and safe delivery of GLP-1AR and FGF-21 plasmids using amino-functionalized dual-mesoporous silica nanoparticles in vitro and in vivo

Cited by 20 publications

References 45 publications

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine

Mesoporous Silica Nanoparticles: Drug Delivery Vehicles for Antidiabetic Molecules

Delivery of Therapeutic Biopolymers Employing Silica-Based Nanosystems

Contact Info

Product

Resources

About